Wegovy 0.5 mg Prefilled Pen

Wegovy 0.5 mg FlexTouch is a pre-filled pen containing semaglutide, a GLP-1 receptor agonist used as part of a comprehensive weight-management programme. Wegovy is used alongside a reduced-calorie diet and increased physical activity for eligible patients. The medicine is supplied as a prescription-only medicine in the UK.

What is Wegovy 0.5 mg?

Wegovy 0.5 mg contains semaglutide and is administered by subcutaneous injection once weekly according to the prescribed treatment schedule. The 0.5 mg strength is one of the dose-escalation strengths used during Wegovy treatment. Your healthcare professional should determine whether Wegovy is appropriate for you and how your treatment should be progressed.

Wegovy works by acting on receptors associated with the natural hormone GLP-1. It can influence appetite and feelings of fullness, helping eligible patients reduce food intake as part of an overall weight-management programme.

Wegovy 0.5 mg dose

For eligible adults, Wegovy treatment is normally introduced at a lower dose before gradually increasing the dose at intervals determined by the prescribing information and healthcare professional. 0.5 mg is a dose-escalation strength and should not be treated as a starting dose unless specifically prescribed.

Do not change your dose, frequency or treatment schedule without speaking to your prescriber.

Who may be prescribed Wegovy?

Wegovy is authorised for weight management in eligible patients meeting the criteria specified in the current UK prescribing information. Suitability depends on factors such as body mass index, age, existing health conditions and other medicines being taken.

For full eligibility requirements, see the Wegovy patient information leaflet and Wegovy prescribing information.

Important safety information

Wegovy is a prescription medicine and should only be used under the supervision of an appropriately qualified healthcare professional.

Patients should read the official patient information leaflet before treatment. Possible adverse effects and precautions are described in the official UK product information. Seek medical advice if you experience concerning or severe symptoms.

Wegovy should be stored and handled according to the official product instructions. The pen should only be used by the person for whom it was prescribed, and needles should be disposed of according to local requirements.

Related information

If you are researching semaglutide treatments, see our [Wegovy 0.25 mg Prefilled Pen] and [Wegovy 1.0 mg Prefilled Pen] pages for information about the other strengths in the Wegovy range.

You can also read our [Weight Management Guide] for general educational information about prescription weight-management treatments.

For authoritative UK medicine information, consult the electronic Medicines Compendium (eMC) and speak with your doctor, pharmacist or other qualified healthcare professional.

Frequently Asked Questions
Is Wegovy 0.5 mg a prescription medicine?

Yes. Wegovy is classified as a prescription-only medicine in the UK. It should only be supplied and used in accordance with applicable prescription requirements.

What is the active ingredient in Wegovy 0.5 mg?

The active ingredient is semaglutide.

How often is Wegovy 0.5 mg administered?

Wegovy is administered once weekly according to the prescribed treatment schedule. Follow the instructions provided by your healthcare professional and the official patient leaflet.

Is 0.5 mg the starting dose of Wegovy?

No. Wegovy treatment is generally introduced at a lower dose and increased gradually according to the prescribing schedule. The 0.5 mg strength is used during dose escalation.

Can I change my Wegovy dose myself?

No. Dose changes should be made only under the direction of your prescribing healthcare professional.

Where can I find official information about Wegovy?

The UK electronic Medicines Compendium provides the current patient leaflet and professional prescribing information for Wegovy.